In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Pharming Group, with a price target of $37.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily driven by Pharming Group’s strong financial performance and promising growth prospects. The company reported a significant increase in revenue for the second quarter of 2025, surpassing expectations with $93.2 million compared to the estimated $83.26 million. This growth was fueled by higher-than-expected sales of Ruconest and Joenja, with Ruconest generating $80.4 million and Joenja contributing $12.8 million.
Additionally, Pharming Group’s strategic developments and upcoming milestones further support the Buy rating. The company has increased its total revenue guidance, reflecting confidence in continued growth. Moreover, the expansion of Joenja’s addressable market, supported by recent studies, suggests a potential increase in patient eligibility and market size. These factors, coupled with ongoing regulatory advancements and anticipated data readouts, position Pharming Group for sustained growth and justify the Buy recommendation.